210 related articles for article (PubMed ID: 35264436)
21. The effect of Fas/FasL pathway blocking on apoptosis and stemness within breast cancer tumor microenvironment (preclinical study).
Abou Shousha S; Baheeg S; Ghoneim H; Zoheir M; Hemida M; Shahine Y
Breast Dis; 2023; 42(1):163-176. PubMed ID: 37334575
[TBL] [Abstract][Full Text] [Related]
22. An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.
Snell D; Gunde T; Warmuth S; Chatterjee B; Brock M; Hess C; Johansson M; Simonin A; Spiga FM; Weinert C; Kirk N; Bassler N; Campos Carrascosa L; Flückiger N; Heiz R; Wagen S; Giezendanner N; Alberti A; Yaman Y; Mahler D; Diem D; Lichtlen P; Urech D
Oncoimmunology; 2023; 12(1):2233401. PubMed ID: 37456982
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
[TBL] [Abstract][Full Text] [Related]
24. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
25. Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the
Lah S; Kim S; Kang I; Kim H; Hupperetz C; Jung H; Choi HR; Lee YH; Jang HK; Bae S; Kim CH
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37019470
[TBL] [Abstract][Full Text] [Related]
26. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X
Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021
[TBL] [Abstract][Full Text] [Related]
27. Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion.
Pinkoski MJ; Droin NM; Lin T; Genestier L; Ferguson TA; Green DR
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16174-9. PubMed ID: 12454289
[TBL] [Abstract][Full Text] [Related]
28. Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy.
McKenzie C; El-Kholy M; Parekh F; Robson M; Lamb K; Allen C; Sillibourne J; Cordoba S; Thomas S; Pule M
Mol Ther Nucleic Acids; 2023 Jun; 32():603-621. PubMed ID: 37200859
[TBL] [Abstract][Full Text] [Related]
29. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
Zaks TZ; Chappell DB; Rosenberg SA; Restifo NP
J Immunol; 1999 Mar; 162(6):3273-9. PubMed ID: 10092779
[TBL] [Abstract][Full Text] [Related]
30. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
31. Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer.
Mondal T; Gaur H; Wamba BEN; Michalak AG; Stout C; Watson MR; Aleixo SL; Singh A; Condello S; Faller R; Leiserowitz GS; Bhatnagar S; Tushir-Singh J
Cell Death Differ; 2023 Nov; 30(11):2408-2431. PubMed ID: 37838774
[TBL] [Abstract][Full Text] [Related]
32. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z
Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286
[TBL] [Abstract][Full Text] [Related]
33. TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma.
Hussein MS; Li Q; Mao R; Peng Y; He Y
Front Immunol; 2023; 14():1114770. PubMed ID: 37215108
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
35. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ.
Radoja S; Saio M; Frey AB
J Immunol; 2001 May; 166(10):6074-83. PubMed ID: 11342625
[TBL] [Abstract][Full Text] [Related]
36. Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy.
Aboelella NS; Brandle C; Okoko O; Gazi MY; Ding ZC; Xu H; Gorman G; Bollag R; Davila ML; Bryan LJ; Munn DH; Piazza GA; Zhou G
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35882449
[TBL] [Abstract][Full Text] [Related]
37. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
[TBL] [Abstract][Full Text] [Related]
38. Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway.
Cheng WF; Lee CN; Chang MC; Su YN; Chen CA; Hsieh CY
Mol Ther; 2005 Nov; 12(5):960-8. PubMed ID: 15979942
[TBL] [Abstract][Full Text] [Related]
39. Topotecan enhances immune clearance of gliomas.
Wei J; DeAngulo G; Sun W; Hussain SF; Vasquez H; Jordan J; Weinberg J; Wolff J; Koshkina N; Heimberger AB
Cancer Immunol Immunother; 2009 Feb; 58(2):259-70. PubMed ID: 18594817
[TBL] [Abstract][Full Text] [Related]
40. Retinoids induce Fas(CD95) ligand cell surface expression via RARgamma and nur77 in T cells.
Tóth B; Ludányi K; Kiss I; Reichert U; Michel S; Fésüs L; Szondy Z
Eur J Immunol; 2004 Mar; 34(3):827-836. PubMed ID: 14991612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
